Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients
Open Access
- 3 January 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 39716
Abstract
This study describes specific patterns of elevated inflammatory proteins in clinical subtypes of myasthenia gravis (MG) patients. MG is a chronic, autoimmune neuromuscular disease with antibodies most commonly targeting the acetylcholine receptors (AChRab), which causes fluctuating skeletal muscle fatigue. MG pathophysiology includes a strong component of inflammation, and a large proportion of patients with early onset MG additionally present thymus hyperplasia. Due to the fluctuating nature and heterogeneity of the disease, there is a great need for objective biomarkers as well as novel potential inflammatory targets. We examined the sera of 45 MG patients (40 AChRab seropositive and 5 AChRab seronegative), investigating 92 proteins associated with inflammation. Eleven of the analysed proteins were significantly elevated compared to healthy controls, out of which the three most significant were: matrix metalloproteinase 10 (MMP-10; p = 0.0004), transforming growth factor alpha (TGF-α; p = 0.0017) and extracellular newly identified receptor for advanced glycation end-products binding protein (EN-RAGE) (also known as protein S100-A12; p = 0.0054). Further, levels of MMP-10, C-X-C motif ligand 1 (CXCL1) and brain derived neurotrophic factor (BDNF) differed between early and late onset MG. These novel targets provide valuable additional insight into the systemic inflammatory response in MG.Keywords
This publication has 49 references indexed in Scilit:
- Myasthenia gravis: a clinical-immunological updateJournal of Neurology, 2015
- Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patientsEuropean Cytokine Network, 2015
- Circulating miRNAs in myasthenia gravis: miR‐150‐5p as a new potential biomarkerAnnals of Clinical and Translational Neurology, 2013
- Receptor for Advanced Glycation End Products and Its Involvement in Inflammatory DiseasesInternational Journal of Inflammation, 2013
- Myasthenia and related disorders of the neuromuscular junctionJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Transforming growth factor-alpha induces neurogenesis and behavioral improvement in a chronic stroke modelNeuroscience, 2009
- Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityThe Lancet Neurology, 2009
- Invited Article: Inhibition of B cell functionsNeurology, 2008
- Key Metalloproteinases Are Expressed by Specific Cell Types in Experimental Autoimmune EncephalomyelitisThe Journal of Immunology, 2004
- Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodiesNature Medicine, 2001